Sam Lockhart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sam Lockhart has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
- Stephen O’rAhilly
Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom
9 shared publications - John R. B. Perry
Metabolic Research Laboratory, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK
7 shared publications - Yajie Zhao
IMS Epidemiology, Institute of Metabolic Science, University of Cambridge, Cambridge, UK
7 shared publications - Felix R. Day
University of Cambridge
6 shared publications - Katherine A. Kentistou
Medical Research Council Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK
6 shared publications - Brian Yee Hong Lam
University of Cambridge
5 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (11) , 2794-2803
Genome-wide mapping of common and rare variant effects on adiposity across childhood
Our understanding of the genetic architecture of obesity is primarily based on studies of adults, with sparser data from childhood. Here, we conducted age-stratified genetic association studies against objectively measured ( n = 62,276) or recalled childhood adiposity-related traits ( n eff = 599,924), identifying 624 common variants associated with childhood adiposity, with one-third having no concordant association with adult body mass index. Signals linked to the leptin–melanocortin pathway ( BSX , GNAS , LEPR and PCSK1 ) and incretin signaling ( GIPR and GLP1R ) showed childhood-specific effects on adiposity. Single-nucleus RNA sequencing data identified childhood-specific adiposity-regulating cell populations in the arcuate nucleus and mammillary bodies, indicating neurocircuits that regulate adiposity specifically during childhood. Finally, sequencing in 479,615 individuals uncovered rare protein-coding variation in ADCY3 , CALCR , MC4R , MRAP2 , POMC and MYH13 , exhibiting stronger associations in childhood than in adults. Our findings suggest that childhood provides a more sensitive window for the study of key endocrine and neuropeptide pathways that regulate energy balance.
- 25 September 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (11) , 2794-2803
Open AccessGenome-wide mapping of common and rare variant effects on adiposity across childhood
Our understanding of the genetic architecture of obesity is primarily based on studies of adults, with sparser data from childhood. Here, we conducted age-stratified genetic association studies against objectively measured ( n = 62,276) or recalled childhood adiposity-related traits ( n eff = 599,924), identifying 624 common variants associated with childhood adiposity, with one-third having no concordant association with adult body mass index. Signals linked to the leptin–melanocortin pathway ( BSX , GNAS , LEPR and PCSK1 ) and incretin signaling ( GIPR and GLP1R ) showed childhood-specific effects on adiposity. Single-nucleus RNA sequencing data identified childhood-specific adiposity-regulating cell populations in the arcuate nucleus and mammillary bodies, indicating neurocircuits that regulate adiposity specifically during childhood. Finally, sequencing in 479,615 individuals uncovered rare protein-coding variation in ADCY3 , CALCR , MC4R , MRAP2 , POMC and MYH13 , exhibiting stronger associations in childhood than in adults. Our findings suggest that childhood provides a more sensitive window for the study of key endocrine and neuropeptide pathways that regulate energy balance.
- Open Access
Statin Use and Genetically Predicted HMG-CoA Reductase Inhibition in Relation to Clonal Hematopoiesis
Background: Clonal hematopoiesis (CH) is associated with increased risks of diverse cardiovascular diseases, hematologic malignancies and mortality, yet no preventive therapies are approved. As emerging data implicate lipid pathways in CH pathogenesis, we investigated the association of statin use and genetically proxied inhibition of HMG-CoA reductase (HMGCR) with CH risk, and validated findings using primary peripheral blood mononuclear cells (PBMCs). Methods: We performed an observational analysis of 416,118 UK Biobank participants of European ancestry using multivariable logistic regression to compare CH prevalence among statin users and nonusers. Mendelian randomization (MR) analyses evaluated the causal association of genetically proxied lowering of low-density lipoprotein cholesterol (LDL-C) with risk of CH using two instruments; (i) the lead HMGCR variant (rs12916) which proxied LDL-C lowering by statins, and, (ii) 303 genome-wide LDL-C-lowering variants representing polygenic mechanisms. Summary statistics were obtained from the Global Lipid Genetics Consortium genome-wide association study (N = 842,634). Experimentally, primary PBMCs from a DNMT3A R882 hotspot mutation carrier were cultured in methylcellulose with pravastatin or vehicle control to evaluate colony-forming dynamics. Results: Among 416,118 individuals, 20,488 had CH, including 11,550 with single DNMT3A -mutant and 4,375 with single TET2 -mutant CH. Pre-recruitment statin users had reduced odds of DNMT3A -mutant CH (OR=0.93; 95% CI:0.88-0.98; P =0.009), driven primarily by associations with DNMT3A R882 –mutant (OR=0.78; 95% CI:0.66-0.92; P =0.003), but not TET2 -mutant CH (OR=1.05; 95% CI:0.97-1.14; P =0.20). Similarly, genetically predicted HMG-CoA-reductase inhibition equivalent to a 1 SD reduction in circulating LDL-C levels was associated with lower odds of DNMT3A -mutant CH (OR=0.66; 95% CI:0.45-0.95; P =0.03) but not TET2 -mutant CH (OR=1.34; 95% CI:0.76-2.36; P = 0.31). By contrast, polygenic estimation of LDL-C lowering was not associated with DNMT3A -mutant CH (OR=1.05; 95% CI:0.97-1.14; P =0.20), suggesting protective effects were independent of LDL-C lowering per se. Genetically predicted HMG-CoA reductase inhibition had wide effects on blood cell counts and indices, suggesting effects on bone marrow cell dynamics. In vitro , pravastatin selectively suppressed colony formation of primary human DNMT3A R882 –mutant relative to wild-type cells (P=0.031). Conclusions: Statin therapy and genetically predicted lifelong inhibition of HMG-CoA reductase were significantly associated with reduced risk of DNMT3A -mutant CH, likely via LDL-C-independent mechanisms, which may be specific to DNMT3A -mutant CH. This provides a strong rationale for prospective trials evaluating the effect of statins on risk of developing DNMT3A -mutant CH, subsequent clonal expansion, and associated clinical sequelae. Clinical Perspectives: What is new?: This study provides the first evidence that statins may protect against DNMT3A -mutant clonal hematopoiesis (CH), with convergent findings of observational analysis of statin users and genetic epidemiology utilizing Mendelian randomization to proxy lifelong HMG-CoA reductase inhibition. Observational analyses suggest the protective effect may be strongest against DNMT3A R882 –mutant CH. We provide evidence that pravastatin selectively suppresses colony formation of primary human DNMT3A R882 –mutant primary peripheral blood mononuclear cells in vitro , suggesting a possible effect on clonal expansion. What are the clinical implications?: Although DNMT3A -mutant CH is associated with diverse cardiovascular diseases, hematological malignancies and mortality, no preventive treatments are currently established; this study provides a viable avenue for future interventional studies. These data establish a strong rationale for prospective trials evaluating whether statins prevent the development or expansion of DNMT3A -mutant CH and its cardiovascular consequences. Given that statins are widely used with established safety profiles, affordable and have proven cardiovascular benefit, such trials are readily implementable.
Open AccessStatin Use and Genetically Predicted HMG-CoA Reductase Inhibition in Relation to Clonal Hematopoiesis
Background: Clonal hematopoiesis (CH) is associated with increased risks of diverse cardiovascular diseases, hematologic malignancies and mortality, yet no preventive therapies are approved. As emerging data implicate lipid pathways in CH pathogenesis, we investigated the association of statin use and genetically proxied inhibition of HMG-CoA reductase (HMGCR) with CH risk, and validated findings using primary peripheral blood mononuclear cells (PBMCs). Methods: We performed an observational analysis of 416,118 UK Biobank participants of European ancestry using multivariable logistic regression to compare CH prevalence among statin users and nonusers. Mendelian randomization (MR) analyses evaluated the causal association of genetically proxied lowering of low-density lipoprotein cholesterol (LDL-C) with risk of CH using two instruments; (i) the lead HMGCR variant (rs12916) which proxied LDL-C lowering by statins, and, (ii) 303 genome-wide LDL-C-lowering variants representing polygenic mechanisms. Summary statistics were obtained from the Global Lipid Genetics Consortium genome-wide association study (N = 842,634). Experimentally, primary PBMCs from a DNMT3A R882 hotspot mutation carrier were cultured in methylcellulose with pravastatin or vehicle control to evaluate colony-forming dynamics. Results: Among 416,118 individuals, 20,488 had CH, including 11,550 with single DNMT3A -mutant and 4,375 with single TET2 -mutant CH. Pre-recruitment statin users had reduced odds of DNMT3A -mutant CH (OR=0.93; 95% CI:0.88-0.98; P =0.009), driven primarily by associations with DNMT3A R882 –mutant (OR=0.78; 95% CI:0.66-0.92; P =0.003), but not TET2 -mutant CH (OR=1.05; 95% CI:0.97-1.14; P =0.20). Similarly, genetically predicted HMG-CoA-reductase inhibition equivalent to a 1 SD reduction in circulating LDL-C levels was associated with lower odds of DNMT3A -mutant CH (OR=0.66; 95% CI:0.45-0.95; P =0.03) but not TET2 -mutant CH (OR=1.34; 95% CI:0.76-2.36; P = 0.31). By contrast, polygenic estimation of LDL-C lowering was not associated with DNMT3A -mutant CH (OR=1.05; 95% CI:0.97-1.14; P =0.20), suggesting protective effects were independent of LDL-C lowering per se. Genetically predicted HMG-CoA reductase inhibition had wide effects on blood cell counts and indices, suggesting effects on bone marrow cell dynamics. In vitro , pravastatin selectively suppressed colony formation of primary human DNMT3A R882 –mutant relative to wild-type cells (P=0.031). Conclusions: Statin therapy and genetically predicted lifelong inhibition of HMG-CoA reductase were significantly associated with reduced risk of DNMT3A -mutant CH, likely via LDL-C-independent mechanisms, which may be specific to DNMT3A -mutant CH. This provides a strong rationale for prospective trials evaluating the effect of statins on risk of developing DNMT3A -mutant CH, subsequent clonal expansion, and associated clinical sequelae. Clinical Perspectives: What is new?: This study provides the first evidence that statins may protect against DNMT3A -mutant clonal hematopoiesis (CH), with convergent findings of observational analysis of statin users and genetic epidemiology utilizing Mendelian randomization to proxy lifelong HMG-CoA reductase inhibition. Observational analyses suggest the protective effect may be strongest against DNMT3A R882 –mutant CH. We provide evidence that pravastatin selectively suppresses colony formation of primary human DNMT3A R882 –mutant primary peripheral blood mononuclear cells in vitro , suggesting a possible effect on clonal expansion. What are the clinical implications?: Although DNMT3A -mutant CH is associated with diverse cardiovascular diseases, hematological malignancies and mortality, no preventive treatments are currently established; this study provides a viable avenue for future interventional studies. These data establish a strong rationale for prospective trials evaluating whether statins prevent the development or expansion of DNMT3A -mutant CH and its cardiovascular consequences. Given that statins are widely used with established safety profiles, affordable and have proven cardiovascular benefit, such trials are readily implementable.
- Open Access
- 2 January 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (1)
Human genetics suggests differing causal pathways from HMGCR inhibition to coronary artery disease and type 2 diabetes
Background: Statins lower low-density lipoprotein cholesterol (LDL-C) and reduce the risk of coronary artery disease (CAD). However, they also increase the risk of type 2 diabetes (T2D). Methods: We consider genetic variants in the region of the HMGCR gene, which encodes the target of statins, and their associations with downstream consequences of statins. We use various statistical methods to identify causal pathways influencing CAD and T2D, and investigate whether these are the same or different for the two diseases. Results: Colocalization analyses indicate that LDL-C and body mass index (BMI) have distinct genetic predictors in this gene region, suggesting that they do not lie on the same causal pathway. Multivariable Mendelian randomization analyses restricted to variants in the HMGCR gene region revealed LDL-C and BMI as causal risk factors for CAD, and BMI as a causal risk factor for T2D, but not LDL-C. A Bayesian model averaging method prioritized BMI as the most likely causal risk factor for T2D, and LDL-C as the second most likely causal risk factor for CAD (behind ubiquinone). Colocalization analyses provided consistent evidence of LDL-C colocalizing with CAD, and BMI colocalizing with T2D; evidence was inconsistent for colocalization of LDL-C with T2D, and BMI with CAD. Conclusions: Our analyses suggest cardiovascular and metabolic consequences of statin usage are on different causal pathways, and hence could be influenced separately by targeted interventions. More broadly, our analysis workflow offers potential insights to identify pathway-specific causal risk factors that could provide possible repositioning or refinement opportunities for existing drug targets.
- 2 January 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (1)
Open AccessHuman genetics suggests differing causal pathways from HMGCR inhibition to coronary artery disease and type 2 diabetes
Background: Statins lower low-density lipoprotein cholesterol (LDL-C) and reduce the risk of coronary artery disease (CAD). However, they also increase the risk of type 2 diabetes (T2D). Methods: We consider genetic variants in the region of the HMGCR gene, which encodes the target of statins, and their associations with downstream consequences of statins. We use various statistical methods to identify causal pathways influencing CAD and T2D, and investigate whether these are the same or different for the two diseases. Results: Colocalization analyses indicate that LDL-C and body mass index (BMI) have distinct genetic predictors in this gene region, suggesting that they do not lie on the same causal pathway. Multivariable Mendelian randomization analyses restricted to variants in the HMGCR gene region revealed LDL-C and BMI as causal risk factors for CAD, and BMI as a causal risk factor for T2D, but not LDL-C. A Bayesian model averaging method prioritized BMI as the most likely causal risk factor for T2D, and LDL-C as the second most likely causal risk factor for CAD (behind ubiquinone). Colocalization analyses provided consistent evidence of LDL-C colocalizing with CAD, and BMI colocalizing with T2D; evidence was inconsistent for colocalization of LDL-C with T2D, and BMI with CAD. Conclusions: Our analyses suggest cardiovascular and metabolic consequences of statin usage are on different causal pathways, and hence could be influenced separately by targeted interventions. More broadly, our analysis workflow offers potential insights to identify pathway-specific causal risk factors that could provide possible repositioning or refinement opportunities for existing drug targets.
- Open Access
- 1 December 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (6) , e005233
Rare Variants in HTRA1, SGTB, and RBM12 Confer Risk of Atherosclerotic Cardiovascular Disease Independent of Traditional Cardiovascular Risk Factors
BACKGROUND: Atherosclerosis is a pathophysiological process common to a range of cardiovascular diseases. We reasoned that considering clinical presentations of atherosclerosis across the coronary, peripheral, and cerebrovasculature as a single entity would enhance statistical power to identify rare genetic variation driving pathological processes across multiple vascular beds. METHODS: We performed an exome-wide association study of atherosclerotic cardiovascular disease in 434 438 UK Biobank participants of European ancestry. RESULTS: We identified rare, predicted damaging variants in HTRA1, SGTB, and RBM12 to be associated with risk of atherosclerotic cardiovascular disease, independent of known risk factors. Both SGTB and HTRA1 were downregulated in the aorta of patients with coronary artery disease compared with controls. Loss-of-function variants in the RNA-binding protein RBM12 increased the risk of coronary, cerebrovascular, and peripheral vascular diseases to a similar extent. SGTB increased the risk of atherosclerotic cardiovascular disease in the coronary and peripheral circulations but not the cerebrovasculature. While loss-of-function variants in HTRA1 are known to cause monogenic stroke syndromes, we found that damaging missense variants in HTRA1 are associated with increased risk of disease in both the cerebrovascular and coronary circulation. Surprisingly, the increased risk of coronary artery disease was driven predominantly by a single missense variant (p.R227W; minor allele frequency, 0.009). In vitro, the R227W mutant HTRA1 efficiently proteolyzed the disordered substrate casein but not aggregated α-synuclein. In contrast, a stroke risk–raising variant (D320N) could not efficiently process any of the tested substrates. CONCLUSIONS: We identified novel genetic variants predisposing to atherosclerotic cardiovascular diseases that act independently of established cardiovascular risk factors. The observed phenotypic and functional heterogeneities between HTRA1 variants suggest that distinct biochemical mechanisms drive HTRA1-related vascular disease in the brain and heart.
- 1 December 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (6) , e005233
Open AccessRare Variants in HTRA1, SGTB, and RBM12 Confer Risk of Atherosclerotic Cardiovascular Disease Independent of Traditional Cardiovascular Risk Factors
BACKGROUND: Atherosclerosis is a pathophysiological process common to a range of cardiovascular diseases. We reasoned that considering clinical presentations of atherosclerosis across the coronary, peripheral, and cerebrovasculature as a single entity would enhance statistical power to identify rare genetic variation driving pathological processes across multiple vascular beds. METHODS: We performed an exome-wide association study of atherosclerotic cardiovascular disease in 434 438 UK Biobank participants of European ancestry. RESULTS: We identified rare, predicted damaging variants in HTRA1, SGTB, and RBM12 to be associated with risk of atherosclerotic cardiovascular disease, independent of known risk factors. Both SGTB and HTRA1 were downregulated in the aorta of patients with coronary artery disease compared with controls. Loss-of-function variants in the RNA-binding protein RBM12 increased the risk of coronary, cerebrovascular, and peripheral vascular diseases to a similar extent. SGTB increased the risk of atherosclerotic cardiovascular disease in the coronary and peripheral circulations but not the cerebrovasculature. While loss-of-function variants in HTRA1 are known to cause monogenic stroke syndromes, we found that damaging missense variants in HTRA1 are associated with increased risk of disease in both the cerebrovascular and coronary circulation. Surprisingly, the increased risk of coronary artery disease was driven predominantly by a single missense variant (p.R227W; minor allele frequency, 0.009). In vitro, the R227W mutant HTRA1 efficiently proteolyzed the disordered substrate casein but not aggregated α-synuclein. In contrast, a stroke risk–raising variant (D320N) could not efficiently process any of the tested substrates. CONCLUSIONS: We identified novel genetic variants predisposing to atherosclerotic cardiovascular diseases that act independently of established cardiovascular risk factors. The observed phenotypic and functional heterogeneities between HTRA1 variants suggest that distinct biochemical mechanisms drive HTRA1-related vascular disease in the brain and heart.
- Open Access
- 10 October 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (10) , 2436-2444
Population-scale gene-based analysis of whole-genome sequencing provides insights into metabolic health
In addition to its coverage of the noncoding genome, whole-genome sequencing (WGS) may better capture the coding genome than exome sequencing. Here we sought to exploit this and identify new rare, protein-coding variants associated with metabolic health in WGS data (n = 708,956) from the UK Biobank and All of Us studies. Identified genes highlight new biological mechanisms, including protein-truncating variants (PTVs) in the DNA double-strand break repair gene RIF1 that have a substantial effect on body mass index (2.66 kg m− 2, s.e. 0.43, P = 3.7 × 10−10). UBR3 is an intriguing example where PTVs independently increase body mass index and type 2 diabetes risk. Furthermore, PTVs in IRS2 have a substantial effect on type 2 diabetes (odds ratio 6.4 (3.7–11.3), P = 9.9 × 10−14, 34% case prevalence among carriers) and were also associated with chronic kidney disease independent of diabetes status, suggesting an important role for IRS2 in maintaining renal health. Our study demonstrates that large-scale WGS provides new mechanistic insights into human metabolic phenotypes through improved capture of coding sequences.
- 10 October 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (10) , 2436-2444
Open AccessPopulation-scale gene-based analysis of whole-genome sequencing provides insights into metabolic health
In addition to its coverage of the noncoding genome, whole-genome sequencing (WGS) may better capture the coding genome than exome sequencing. Here we sought to exploit this and identify new rare, protein-coding variants associated with metabolic health in WGS data (n = 708,956) from the UK Biobank and All of Us studies. Identified genes highlight new biological mechanisms, including protein-truncating variants (PTVs) in the DNA double-strand break repair gene RIF1 that have a substantial effect on body mass index (2.66 kg m− 2, s.e. 0.43, P = 3.7 × 10−10). UBR3 is an intriguing example where PTVs independently increase body mass index and type 2 diabetes risk. Furthermore, PTVs in IRS2 have a substantial effect on type 2 diabetes (odds ratio 6.4 (3.7–11.3), P = 9.9 × 10−14, 34% case prevalence among carriers) and were also associated with chronic kidney disease independent of diabetes status, suggesting an important role for IRS2 in maintaining renal health. Our study demonstrates that large-scale WGS provides new mechanistic insights into human metabolic phenotypes through improved capture of coding sequences.
- Open Access
- 3 June 2025
- Published by Springer Nature in Research Square
The role of common and rare genetic variation on adiposity across childhood.
Our understanding of the genetic architecture of obesity has primarily been shaped by observations from adult populations with relatively few studies on childhood obesity. To address this gap, we conduct a longitudinal genetic association study in up to ~600,000 individuals with objectively measured or recalled childhood adiposity-related traits. We identify 624 common variant signals (only 7% are previously reported) associated with childhood adiposity, of which one third have no concordant association with adult BMI. Signals linked to the leptin-melanocortin pathway (BSX, GNAS, LEPR and PCSK1) and incretin-signalling genes (GIPR and GLP1R) show stronger associations in childhood than in adults, suggesting that childhood provides a more sensitive window for detecting variation in key endocrine and neuropeptide pathways regulating energy balance. This observation is further supported by integrating single-nucleus RNA sequencing data from the human hypothalamus, identifying childhood-specific adiposity-regulating cell populations in the arcuate nucleus and mammillary bodies, indicating distinct neuro-circuits that regulate adiposity only during childhood. Three signals showed parent-of-origin specific associations with childhood BMI, at KLF14 (maternal-specific), GNAS (parental-discordant) and ZDBF2 (paternal-specific). Finally, we complement these common variant analyses with DNA sequence data in 479,615 individuals, identifying rare protein-coding variation in ADCY3, CALCR, MC4R, MRAP2, POMC and MYH13, all of which demonstrate stronger adiposity associations in childhood than in adults. Collectively, our findings emphasize the value of expanding research on childhood adiposity alongside studies focused on adult obesity measures.
- 3 June 2025
- Published by Springer Nature in Research Square
Open AccessThe role of common and rare genetic variation on adiposity across childhood.
Our understanding of the genetic architecture of obesity has primarily been shaped by observations from adult populations with relatively few studies on childhood obesity. To address this gap, we conduct a longitudinal genetic association study in up to ~600,000 individuals with objectively measured or recalled childhood adiposity-related traits. We identify 624 common variant signals (only 7% are previously reported) associated with childhood adiposity, of which one third have no concordant association with adult BMI. Signals linked to the leptin-melanocortin pathway (BSX, GNAS, LEPR and PCSK1) and incretin-signalling genes (GIPR and GLP1R) show stronger associations in childhood than in adults, suggesting that childhood provides a more sensitive window for detecting variation in key endocrine and neuropeptide pathways regulating energy balance. This observation is further supported by integrating single-nucleus RNA sequencing data from the human hypothalamus, identifying childhood-specific adiposity-regulating cell populations in the arcuate nucleus and mammillary bodies, indicating distinct neuro-circuits that regulate adiposity only during childhood. Three signals showed parent-of-origin specific associations with childhood BMI, at KLF14 (maternal-specific), GNAS (parental-discordant) and ZDBF2 (paternal-specific). Finally, we complement these common variant analyses with DNA sequence data in 479,615 individuals, identifying rare protein-coding variation in ADCY3, CALCR, MC4R, MRAP2, POMC and MYH13, all of which demonstrate stronger adiposity associations in childhood than in adults. Collectively, our findings emphasize the value of expanding research on childhood adiposity alongside studies focused on adult obesity measures.
- Open Access
The role of common and rare genetic variation on adiposity across childhood
Our understanding of the genetic architecture of obesity has primarily been shaped by observations from adult populations with relatively few studies on childhood obesity. To address this gap, we conduct a longitudinal genetic association study in up to ∼600,000 individuals with objectively measured or recalled childhood adiposity-related traits. We identify 624 common variant signals (only 7% are previously reported) associated with childhood adiposity, of which one third have no concordant association with adult BMI. Signals linked to the leptin-melanocortin pathway ( BSX, GNAS , LEPR and PCSK1 ) and incretin-signalling genes ( GIPR and GLP1R ) show stronger associations in childhood than in adults, suggesting that childhood provides a more sensitive window for detecting variation in key endocrine and neuropeptide pathways regulating energy balance. This observation is further supported by integrating single-nucleus RNA sequencing data from the human hypothalamus, identifying childhood-specific adiposity-regulating cell populations in the arcuate nucleus and mammillary bodies, indicating distinct neuro-circuits that regulate adiposity only during childhood. Three signals showed parent-of-origin specific associations with childhood BMI, at KLF14 (maternal-specific), GNAS (parental-discordant) and ZDBF2 (paternal-specific). Finally, we complement these common variant analyses with DNA sequence data in 479,615 individuals, identifying rare protein-coding variation in ADCY3 , CALCR , MC4R , MRAP2 , POMC and MYH13, all of which demonstrate stronger adiposity associations in childhood than in adults. Collectively, our findings emphasize the value of expanding research on childhood adiposity alongside studies focused on adult obesity measures.
Open AccessThe role of common and rare genetic variation on adiposity across childhood
Our understanding of the genetic architecture of obesity has primarily been shaped by observations from adult populations with relatively few studies on childhood obesity. To address this gap, we conduct a longitudinal genetic association study in up to ∼600,000 individuals with objectively measured or recalled childhood adiposity-related traits. We identify 624 common variant signals (only 7% are previously reported) associated with childhood adiposity, of which one third have no concordant association with adult BMI. Signals linked to the leptin-melanocortin pathway ( BSX, GNAS , LEPR and PCSK1 ) and incretin-signalling genes ( GIPR and GLP1R ) show stronger associations in childhood than in adults, suggesting that childhood provides a more sensitive window for detecting variation in key endocrine and neuropeptide pathways regulating energy balance. This observation is further supported by integrating single-nucleus RNA sequencing data from the human hypothalamus, identifying childhood-specific adiposity-regulating cell populations in the arcuate nucleus and mammillary bodies, indicating distinct neuro-circuits that regulate adiposity only during childhood. Three signals showed parent-of-origin specific associations with childhood BMI, at KLF14 (maternal-specific), GNAS (parental-discordant) and ZDBF2 (paternal-specific). Finally, we complement these common variant analyses with DNA sequence data in 479,615 individuals, identifying rare protein-coding variation in ADCY3 , CALCR , MC4R , MRAP2 , POMC and MYH13, all of which demonstrate stronger adiposity associations in childhood than in adults. Collectively, our findings emphasize the value of expanding research on childhood adiposity alongside studies focused on adult obesity measures.
- Open Access
- 28 February 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (11) , e3774-e3782
Effects of Rare Coding Variants in Severe Early-Onset Obesity Genes in the Population-Based UK Biobank Study
Context: Clinical case–based studies have identified rare pathogenic variants in several genes as causes of severe early-onset obesity, but their penetrance and interaction with polygenic susceptibility in the general population remain unclear. Objective: We analyzed the United Kingdom Biobank (UKBB) whole-exome sequence data to assess the effects of heterozygous variants in 9 previously reported genes on adult body mass index (BMI) and recalled childhood adiposity. Methods: Among 419 581 UKBB participants, we identified heterozygous carriers of coding variants that were (1) experimentally characterized as loss of function (LoF), or (2) bioinformatically predicted as rare (minor allele frequency .05). For bioinformatically predicted rare LoF variants, gene-based burden tests showed that carriage of heterozygous variants in MC4R, PCSK1, and POMC was associated with higher adult BMI (effect sizes ranged from 0.5 to 2.5 kg/m2, all P < .003), with no significant interaction effects with common variant polygenic risk of BMI. Conclusion: This study provides the population-specific report of variant penetrance of known obesity genes and confirmed the heterozygous rare variant effects in MC4R, POMC, and PCSK1. We also underscore the utility of population-based studies in supporting variant classifications.
- 28 February 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (11) , e3774-e3782
Open AccessEffects of Rare Coding Variants in Severe Early-Onset Obesity Genes in the Population-Based UK Biobank Study
Context: Clinical case–based studies have identified rare pathogenic variants in several genes as causes of severe early-onset obesity, but their penetrance and interaction with polygenic susceptibility in the general population remain unclear. Objective: We analyzed the United Kingdom Biobank (UKBB) whole-exome sequence data to assess the effects of heterozygous variants in 9 previously reported genes on adult body mass index (BMI) and recalled childhood adiposity. Methods: Among 419 581 UKBB participants, we identified heterozygous carriers of coding variants that were (1) experimentally characterized as loss of function (LoF), or (2) bioinformatically predicted as rare (minor allele frequency .05). For bioinformatically predicted rare LoF variants, gene-based burden tests showed that carriage of heterozygous variants in MC4R, PCSK1, and POMC was associated with higher adult BMI (effect sizes ranged from 0.5 to 2.5 kg/m2, all P < .003), with no significant interaction effects with common variant polygenic risk of BMI. Conclusion: This study provides the population-specific report of variant penetrance of known obesity genes and confirmed the heterozygous rare variant effects in MC4R, POMC, and PCSK1. We also underscore the utility of population-based studies in supporting variant classifications.
- Open Access
- 25 September 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (10) , 1922-1938
Damaging mutations in liver X receptor-α are hepatotoxic and implicate cholesterol sensing in liver health
Liver X receptor-α (LXRα) regulates cellular cholesterol abundance and potently activates hepatic lipogenesis. Here we show that at least 1 in 450 people in the UK Biobank carry functionally impaired mutations in LXRα, which is associated with biochemical evidence of hepatic dysfunction. On a western diet, male and female mice homozygous for a dominant negative mutation in LXRα have elevated liver cholesterol, diffuse cholesterol crystal accumulation and develop severe hepatitis and fibrosis, despite reduced liver triglyceride and no steatosis. This phenotype does not occur on low-cholesterol diets and can be prevented by hepatocyte-specific overexpression of LXRα. LXRα knockout mice exhibit a milder phenotype with regional variation in cholesterol crystal deposition and inflammation inversely correlating with steatosis. In summary, LXRα is necessary for the maintenance of hepatocyte health, likely due to regulation of cellular cholesterol content. The inverse association between steatosis and both inflammation and cholesterol crystallization may represent a protective action of hepatic lipogenesis in the context of excess hepatic cholesterol.
- 25 September 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (10) , 1922-1938
Open AccessDamaging mutations in liver X receptor-α are hepatotoxic and implicate cholesterol sensing in liver health
Liver X receptor-α (LXRα) regulates cellular cholesterol abundance and potently activates hepatic lipogenesis. Here we show that at least 1 in 450 people in the UK Biobank carry functionally impaired mutations in LXRα, which is associated with biochemical evidence of hepatic dysfunction. On a western diet, male and female mice homozygous for a dominant negative mutation in LXRα have elevated liver cholesterol, diffuse cholesterol crystal accumulation and develop severe hepatitis and fibrosis, despite reduced liver triglyceride and no steatosis. This phenotype does not occur on low-cholesterol diets and can be prevented by hepatocyte-specific overexpression of LXRα. LXRα knockout mice exhibit a milder phenotype with regional variation in cholesterol crystal deposition and inflammation inversely correlating with steatosis. In summary, LXRα is necessary for the maintenance of hepatocyte health, likely due to regulation of cellular cholesterol content. The inverse association between steatosis and both inflammation and cholesterol crystallization may represent a protective action of hepatic lipogenesis in the context of excess hepatic cholesterol.
- Open Access
Damaging mutations in LXRα uncouple lipogenesis from hepatotoxicity and implicate hepatic cholesterol sensing in human liver health
The nuclear receptor Liver X Receptor-α (LXRα) activates lipogenic gene expression in hepatocytes. Its inhibition has therefore been proposed as a strategy to treat metabolic-dysfunction-associated steatotic liver disease (MASLD). In order to understand the impact of reducing LXRα activity on human health we first examined the association between the carriage of rare loss of function mutations in NR1H3 (encoding LXRα) and metabolic and hepatic phenotypes. We identified 63 rare predicted damaging variants in the ligand binding domain of LXRα in 454,787 participants in UK Biobank. On functional characterisation, 42 of these were found to be severely impaired. Consistent with loss of the lipogenic actions of LXRα, carriers of damaging mutations in LXRα had reduced serum triglycerides (ß=-0.13 s.d. ±0.03, P=2.7x10 -5 , N(carriers)=971). Surprisingly, these carriers also had elevated concentrations of serum liver enzymes (e.g. ALT: ß=0.17s.d. ±0.03, P=1.1x10 -8 , N(carriers)=972) with a 35% increased risk of clinically significant elevations in ALT (OR=1.32, 95%CI:1.15-1.53, P=1.2x10 -4 , N(carriers)=972), suggestive of hepatotoxicity. We generated a knock-in mouse carrying one of the most severely damaging mutations ( Nr1h3 p.W441R) which we demonstrated to have dominant negative properties. Homozygous knock-in mice rapidly developed severe hepatitis and fibrotic liver injury following exposure to western diet despite markedly reduced steatosis, liver triglycerides and lipogenic gene expression. This phenotype was completely rescued by viral over-expression of wildtype LXRα specifically in hepatocytes, indicating a cell-autonomous effect of the mutant on hepatocyte health. While homozygous LXRα knockout mice showed some evidence of hepatocyte injury under similar dietary conditions, the phenotype of the LXRα W441R/W441R mouse was much more severe, suggesting that dominant negative mutations that actively co-repress target genes can result in pathological impacts significantly more severe than those seen with simple absence of the receptor. In summary, our results show that loss of function mutations in LXRα occur in at least 1/450 people and are associated with evidence of liver dysfunction. These findings implicate LXRα in the maintenance of human liver health, identify a new murine model of rapidly progressive fibrotic liver disease and caution against LXR antagonism as a therapeutic strategy for MASLD.
Open AccessDamaging mutations in LXRα uncouple lipogenesis from hepatotoxicity and implicate hepatic cholesterol sensing in human liver health
The nuclear receptor Liver X Receptor-α (LXRα) activates lipogenic gene expression in hepatocytes. Its inhibition has therefore been proposed as a strategy to treat metabolic-dysfunction-associated steatotic liver disease (MASLD). In order to understand the impact of reducing LXRα activity on human health we first examined the association between the carriage of rare loss of function mutations in NR1H3 (encoding LXRα) and metabolic and hepatic phenotypes. We identified 63 rare predicted damaging variants in the ligand binding domain of LXRα in 454,787 participants in UK Biobank. On functional characterisation, 42 of these were found to be severely impaired. Consistent with loss of the lipogenic actions of LXRα, carriers of damaging mutations in LXRα had reduced serum triglycerides (ß=-0.13 s.d. ±0.03, P=2.7x10 -5 , N(carriers)=971). Surprisingly, these carriers also had elevated concentrations of serum liver enzymes (e.g. ALT: ß=0.17s.d. ±0.03, P=1.1x10 -8 , N(carriers)=972) with a 35% increased risk of clinically significant elevations in ALT (OR=1.32, 95%CI:1.15-1.53, P=1.2x10 -4 , N(carriers)=972), suggestive of hepatotoxicity. We generated a knock-in mouse carrying one of the most severely damaging mutations ( Nr1h3 p.W441R) which we demonstrated to have dominant negative properties. Homozygous knock-in mice rapidly developed severe hepatitis and fibrotic liver injury following exposure to western diet despite markedly reduced steatosis, liver triglycerides and lipogenic gene expression. This phenotype was completely rescued by viral over-expression of wildtype LXRα specifically in hepatocytes, indicating a cell-autonomous effect of the mutant on hepatocyte health. While homozygous LXRα knockout mice showed some evidence of hepatocyte injury under similar dietary conditions, the phenotype of the LXRα W441R/W441R mouse was much more severe, suggesting that dominant negative mutations that actively co-repress target genes can result in pathological impacts significantly more severe than those seen with simple absence of the receptor. In summary, our results show that loss of function mutations in LXRα occur in at least 1/450 people and are associated with evidence of liver dysfunction. These findings implicate LXRα in the maintenance of human liver health, identify a new murine model of rapidly progressive fibrotic liver disease and caution against LXR antagonism as a therapeutic strategy for MASLD.